NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100 percent biochemical free recurrence rate more than two years post-surgery

Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024

TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process

10 Barrel Brewing Introduces Pub Cerveza: a New Twist on ‘Cheap Fun.’ Series

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

Kura Oncology Reports First Quarter 2024 Financial Results

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

Ascendis Pharma Reports First Quarter 2024 Financial Results

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

Number of voting rights as of April 30, 2024

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Tilray Brands Launches XMG Zero, a New ‘Better for You’ Cannabis Beverage

Athira Pharma to Participate in Upcoming May Conferences

Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings

Regeneron Reports First Quarter 2024 Financial and Operating Results

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

Director/PDMR Shareholding

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024

Ipsen appoints Keira Driansky as EVP, President of North America

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

Novo Nordisk A/S - share repurchase programme

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024

Repligen Reports First Quarter 2024 Financial Results

Widmer Brothers Brewing Launches New Hefe Variety Pack With Revamped Versions of the Original American Hefeweizen

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting

Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease

Janssen to adopt Johnson & Johnson brand as the Company celebrates 100 years of operating in the UK

Better Choice is Encouraged by the Potential DEA Reclassification of Marijuana

AB Science announces a slight delay in the publication of its 2023 annual financial report

Press Release: Annual General Meeting of April 30, 2024

Biocodex Microbiota Foundation Invites Canadian Academics and Scientists to Apply for €25,000 Research Grant to Advance Microbiota’s role Study in health and diseases

RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine

Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

LSL Pharma Group Reports Its Fourth Quarter and Year-End 2023 Results and Highlights

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Combined General Meeting of May 22, 2024 - Availability of preparatory documents

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars